10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, ...

Circular RNAs (circRNAs) are non-coding RNAs that are enriched in the brain and dysregulated in neurodegenerative diseases. Unlike linear RNA or protein biomarkers, circRNAs are highly stable, and are ...

Financing accelerates clinical validation and commercial readiness, as circular RNAs emerge as a new category of brain-derived blood biomarkers with best-in-class performance SAN DIEGO, Dec. 1, 2025 ...

Company taps John R. Quain, Norbert Gleicher, MD, Carol Hanna, Ph.D, Jon Hennebold, Ph.D, and Stephen Turner, Ph.D to its world-class team to advance responsible genomic medicine. NEW YORK, October 30 ...

Deep Genomics, the AI driven genetic medicine company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by early stage ...

10x Genomics Inc - Class A (TXG) shares closed today at 0.1% above its 52 week low of $104.69, giving the company a market cap of $9B. The stock is currently down 29.6% year-to-date, down 40.3% over ...

New clinical data highlights circular RNAs (circRNAs) as a novel, non-invasive blood biomarker platform for the early detection of Alzheimer's Disease (AD). The research demonstrates that circRNAs ...

10x Genomics Inc - Class A (TXG) shares closed today at 1.5% above its 52 week low of $117.01, giving the company a market cap of $11B. The stock is currently down 18.1% year-to-date, down 27.2% over ...